About This Dosing Guide

This guide provides supplementary information for the Psoriasis Biologic Dosing Calculator calculator. It explains the tool's outputs, use cases, and the clinical concepts behind biologic dosing for plaque psoriasis (PsO) and psoriatic arthritis (PsA). The information is intended for licensed healthcare professionals as a supportive educational resource and does not replace clinical judgment or official prescribing information.

Outputs Explained

After inputting the patient's details, the calculator provides a specific dosing regimen based on the selected biologic. Key outputs include:

• Induction Dosing: The initial, often higher or more frequent, dosing schedule required to establish therapeutic levels of the medication. Some biologics may not have a separate induction phase.
• Maintenance Dosing: The ongoing, long-term dosing schedule used after the induction phase is complete.
• Route of Administration: Specifies whether the drug is administered as a subcutaneous injection or an intravenous infusion.
• Dosing Rationale: A brief note explaining the basis for the provided regimen, such as standard adult dosing, pediatric dosing, or weight-based adjustments (e.g., for patients over 100 kg).
• Black Box Warnings: If applicable to the selected drug, the calculator will display relevant Black Box Warnings from the FDA label.

How to Use the Calculator

To determine a dosing schedule, follow these simple steps:

1. Select the Biologic: Choose the desired biologic agent from the dropdown menu (e.g., adalimumab, ustekinumab).
2. Choose the Indication: Select whether the treatment is for Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), or both. Dosing can differ by indication.
3. Enter Patient Age: Input the patient's age in years. This is crucial for distinguishing between adult and pediatric dosing regimens.
4. Enter Patient Weight: Input the patient's weight and select the appropriate units (kg or lbs). Weight is critical for agents with weight-based dosing.
5. Calculate: Click the "Calculate Dose" button to generate the results. Use the "Reset" button to clear all fields.

Dosing Overview

Biologic dosing for psoriasis and psoriatic arthritis is structured to quickly achieve disease control and maintain it over time. This typically involves two distinct phases and varying administration routes.

Induction vs. Maintenance

The induction phase uses a loading dose or a series of closely spaced doses to rapidly achieve a therapeutic drug concentration. For example, secukinumab (Cosentyx) requires weekly dosing for the first five weeks. The maintenance phase begins afterward, with less frequent dosing (e.g., every 4, 8, or 12 weeks) to sustain efficacy.

Weight-Based vs. Fixed Dosing

Some biologics, like infliximab (Remicade), use weight-based dosing (e.g., 5 mg/kg), requiring a precise calculation for each patient. Others, like ustekinumab (Stelara), may use weight-tiered dosing (e.g., 45 mg for patients ≤ 100 kg, 90 mg for patients > 100 kg). Many newer biologics, such as risankizumab (Skyrizi), use a fixed dose for all adults, simplifying administration.

Switching Biologics

Patients may need to switch biologics due to primary failure, secondary loss of efficacy, or adverse events. This tool does not provide guidance on switching. The process of switching requires careful clinical consideration, including determining whether a washout period is necessary. Clinicians should consult the latest clinical guidelines and the prescribing information for both the initial and subsequent biologic agents.

Missed Dose Protocol

If a patient misses a dose, the course of action depends on the specific biologic and how much time has passed since the scheduled administration. General advice is to administer the missed dose as soon as possible and then resume the regular dosing schedule. However, patients should always be advised to contact their healthcare provider for specific instructions. The full prescribing information for each drug contains detailed guidance on managing a missed dose.

Safety Alerts

Frequently Asked Questions (FAQ)

General Use

Is the output from this calculator a substitute for official prescribing information?
No. This tool is for educational and informational purposes only. It is not a substitute for clinical judgment or the official, FDA-approved prescribing information, which should always be consulted before prescribing.

Does the tool account for comorbidities or renal/hepatic impairment?
No. The calculator provides standard dosing based on indication, age, and weight only. Dose adjustments for specific clinical situations like renal or hepatic impairment are not included and require individual clinical assessment.

Dosing Specifics

Why does the ustekinumab (Stelara) dose change at 100 kg?
The approved dosing for ustekinumab is weight-tiered. Clinical trials demonstrated that patients weighing over 100 kg achieve better therapeutic outcomes with a higher 90 mg dose compared to the 45 mg dose used for lighter patients.

How does the calculator handle pediatric dosing?
The tool includes specific FDA-approved pediatric dosing regimens where available, such as for ustekinumab in plaque psoriasis for patients aged 6-17. It uses weight-based or weight-tiered calculations as specified in the drug's label for that population.

What is the difference in dosing for adalimumab (Humira) between PsO and PsA?
For plaque psoriasis, the standard regimen includes a higher induction dose (160 mg at week 0, 80 mg at week 2). For psoriatic arthritis alone, this initial loading dose is not required, and treatment can begin with the maintenance dose.

Why doesn't the calculator show a dose for my specific patient?
If no result is shown, it means a specific dosing regimen matching the entered criteria (drug, indication, age, and weight) is not present in the tool's dataset. This could be because the drug is not approved for that specific combination (e.g., a certain pediatric indication).

How does the tool calculate dosing for intravenous (IV) drugs like infliximab?
For weight-based IV drugs, the calculator uses the formula provided in the label (e.g., 5 mg/kg). It multiplies this factor by the patient's weight (in kg) to determine the total milligram dose per infusion and displays the full induction and maintenance schedule.

How often is the dosing information in the calculator updated?
The tool is updated periodically to reflect new drug approvals or changes in prescribing information. The "Last Updated" date in the tool header indicates the most recent review.

References

This tool is based on publicly available, FDA-approved prescribing information. For complete and up-to-date details, please consult the official sources below.

1. HUMIRA® (adalimumab) Prescribing Information - FDA
2. STELARA® (ustekinumab) Prescribing Information - FDA
3. COSENTYX® (secukinumab) Prescribing Information - FDA
4. TREMFYA® (guselkumab) Prescribing Information - Janssen
5. SKYRIZI® (risankizumab-rzaa) Prescribing Information - FDA
6. REMICADE® (infliximab) Prescribing Information - FDA
7. AAD-NPF Guidelines of care for the management of psoriasis with biologics - American Academy of Dermatology
8. Drugs@FDA Database - U.S. Food and Drug Administration